Life expectancy in lung cancer doubled with new treatments
Lung cancer is the third most common cancer in the world. Lung cancer ranks first in cancer-related deaths. 1.5 million people in the world, 20-25 thousand people in Turkey die every year due to lung cancer. The good news is that with the targeted therapies developed today, in other words smart drugs, the drug known as the “Cuban vaccine” in the world. lung cancer treatmentincrease their success considerably. Medical Oncology Specialist Prof. Dr. Aziz Yazıcı said, “Advances in the treatment of lung cancer increase the rate of coexistence with the disease and can turn this disease into a chronic disease. However, early detection of cancer is of great importance in achieving successful results from treatment.
Immunotherapy: Can extend life expectancy up to 2 times
“Today, promising results are being achieved in the treatment of lung cancer with smart drugs. When patients who are eligible for smart drugs are treated with oral drugs instead of conventional chemotherapy, life expectancy is nearly doubled. Moreover, the side effects are less than chemotherapy. prof. Dr. Writer He continues, stating that immunotherapy or chemotherapy can be given to patients who are not suitable for these drugs:
Lung cancer treatment: Surgery, chemotherapy and radiotherapy
“Immunotherapy can be used in both first and second series therapy in lung cancer. According to the studies; In the advanced stage of lung cancer, successful results can be achieved 2 times more than chemotherapy treatment in immunotherapy method. In addition, patients’ tolerance to the side effects of immunotherapy is also better.
Cuban vaccine offers hope
Another promising development in the treatment of lung cancer is the drug known as the “Cuban vaccine” in the world. Cuban vaccine is an immunotherapeutic agent. Racotumomab is effective in 3rd and 4th “non-small cell” lung cancer. Non-small cell lung cancer accounts for 80-85% of lung cancers. In a Cuban study, the survivors were found to be 20% higher at the end of the first year compared to the unvaccinated group, and 14% more at the end of the second year.
It has been reported recently in small-scale studies that the vaccine can also be effective in small cell lung cancer. It started to be used in many countries after its effectiveness was demonstrated in the Phase II study (which tested whether the drug was effective in lung cancer and the number of patients was usually around 40-50). However, it has not yet received FDA approval because the phase III study (where the drug was compared with standard treatment in lung cancer and included more patients) has not been concluded.
Effective and very few side effects
prof. Dr. The author states that the vaccine provides more benefits when it is given to patients whose tumor regresses or remains stable after chemotherapy in advanced lung cancer. It is very important that the vaccine is effective in lung cancer and has very few side effects. Although the vaccine does not completely cure the disease in advanced lung cancer, it can prolong the life expectancy in months on average. As such, the vaccine should not be expected to replace standard treatment, but should be considered a new method in the treatment of lung cancer.”
New immunotherapeutic drug doubles survival in lung cancer
Creates antibodies that destroy cancer cells
Cancer develops in the human body because cancer cells escape from the immune system. Known as the Cuban vaccine, the drug stimulates the immune system to form antibodies that recognize and destroy cancer cells containing NeuGcGM. While NeuGcGM is not found in normal cells, it is present in 90% of non-small cell lung cancer cells.
In a study conducted on 35 patients with “advanced non-small cell” lung cancer in Turkey; Antibodies against NeuGcGM ganglioside were measured in the sera of lung cancer patients, and after the vaccine was administered, an increase in antibodies against this ganglioside was detected in the serum of the patients with the effect of the vaccine. It was determined that this antibody increase in the serum of the patients after vaccination showed parallelism with survival.
Annual screening saves lives
When all patients diagnosed with lung cancer are taken into account, only 15 percent of patients live longer than 5 years. In the 5th stage, the chance of surviving more than five years is reduced to 5 percent. The reason for this low survival rate is that the disease is diagnosed at an advanced stage. So much so that in approximately 75% of the patients, the diagnosis can only be made in the 3rd and 4th stages. However, while the success rate of treatment is 25% in the 3rd stage, this rate rises to 70-80% when the disease is caught early. For this reason, in order to detect lung cancer at an early stage, people at risk (over 54 years old and have smoked thirty packs of cigarettes a year) should be screened once a year with low-dose computed tomography.